BioSpace News Archive

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve System, announced highlights from PCR London Valves 2023, a leading, annual global valve conference.

Scilex Holding Company announced that one Midwestern and one Southern State voted to add ZTlido® as a preferred agent to their Medicaid Preferred Drug Lists effective as of January 1, 2024.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting 3 posters including two today at the 2023 San Antonio Breast Cancer Symposium® at Henry B. Gonzalez Convention Center, San Antonio, TX.

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA’s FLEX-NK™ bispecific antibodies.

Synaptogenix, Inc. announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, “New Concepts for the Treatment of Neurodegenerative Disorders.” The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences.

Ambu Inc. announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted the company’s aScope 5 Broncho HD a transitional pass-through (TPT) payment.

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure.

Catawba Research announced a new partnership with Elligo Health Research, the largest healthcare-enabling research organization, that will expand access to clinical trials.

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”) announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024.

bit.bio, the company coding human cells for novel cures, has launched ioMotor Neurons as its 12th ioCells product this year.